RMB, totally agree. That's why this board is always so wild with speculation (myself included). Because we literally have no idea what they are doing and what may happen.
As far as GV, my speculation is that they launch an AG when they launch the new formulation, and try to undercut the other generics on price for the MARINE indication. And the new formulation would be for CVD indication only.
If it is truly once a day insurance coverage will not be a problem. Pill burden is a real thing and if you can cut the number of pills and frequency you get higher compliance. If they could maybe combo it with a statin and GLP-1 that might get us the party in Vegas.
Market Data 
Markets 
AI
